1. Home
  2. GYRE vs BKD Comparison

GYRE vs BKD Comparison

Compare GYRE & BKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GYRE
  • BKD
  • Stock Information
  • Founded
  • GYRE 2002
  • BKD 2005
  • Country
  • GYRE United States
  • BKD United States
  • Employees
  • GYRE N/A
  • BKD N/A
  • Industry
  • GYRE Biotechnology: Pharmaceutical Preparations
  • BKD Hospital/Nursing Management
  • Sector
  • GYRE Health Care
  • BKD Health Care
  • Exchange
  • GYRE Nasdaq
  • BKD Nasdaq
  • Market Cap
  • GYRE 1.3B
  • BKD 1.3B
  • IPO Year
  • GYRE N/A
  • BKD 2005
  • Fundamental
  • Price
  • GYRE $13.12
  • BKD $5.23
  • Analyst Decision
  • GYRE
  • BKD Buy
  • Analyst Count
  • GYRE 0
  • BKD 4
  • Target Price
  • GYRE N/A
  • BKD $7.75
  • AVG Volume (30 Days)
  • GYRE 53.3K
  • BKD 1.9M
  • Earning Date
  • GYRE 11-13-2024
  • BKD 11-06-2024
  • Dividend Yield
  • GYRE N/A
  • BKD N/A
  • EPS Growth
  • GYRE N/A
  • BKD N/A
  • EPS
  • GYRE N/A
  • BKD N/A
  • Revenue
  • GYRE $105,033,000.00
  • BKD $2,954,652,000.00
  • Revenue This Year
  • GYRE $25.32
  • BKD $10.20
  • Revenue Next Year
  • GYRE $12.95
  • BKD $4.56
  • P/E Ratio
  • GYRE N/A
  • BKD N/A
  • Revenue Growth
  • GYRE N/A
  • BKD 5.20
  • 52 Week Low
  • GYRE $8.26
  • BKD $4.65
  • 52 Week High
  • GYRE $30.40
  • BKD $8.12
  • Technical
  • Relative Strength Index (RSI)
  • GYRE 41.11
  • BKD 30.82
  • Support Level
  • GYRE $13.07
  • BKD $5.39
  • Resistance Level
  • GYRE $19.00
  • BKD $5.80
  • Average True Range (ATR)
  • GYRE 1.16
  • BKD 0.24
  • MACD
  • GYRE -0.21
  • BKD -0.09
  • Stochastic Oscillator
  • GYRE 7.39
  • BKD 0.35

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

About BKD Brookdale Senior Living Inc.

Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments; Independent Living; Assisted Living and Memory Care; and Continuing Care Retirement Communities (CCRs). Majority of the revenue is generated from the Assisted Living and Memory Care segment that offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees which it receives in exchange for the services provided, and in the form of management fee from certain communities under contract, in exchange for the management services provided.

Share on Social Networks: